This Week in Rheumatology — Aug 6, 2026

Welcome to This Week in Rheumatology. This week we're covering 8 notable papers spanning treatment optimisation in rheumatoid arthritis, connective tissue disease lung involvement and guideline navigation, and two very different attempts to move the needle on osteoarthritis pain. Let's dive in.

We start with two papers that together sharpen how we choose and sequence advanced therapy in rheumatoid arthritis. In The Lancet Rheumatology, an individual patient data meta-analysis pooled sixteen phase three randomised trials of tofacitinib, baricitinib and upadacitinib, nearly twelve thousand participants, obtained through the Vivli data-sharing platform, to ask whether body mass index modifies response to Janus kinase inhibitors [2]. Almost a third of patients had obesity. Response fell progressively as body mass index rose: compared with patients at healthy weight, the likelihood of achieving an ACR20 response was about six percent lower with overweight, roughly a tenth lower with class one and class two obesity, and about a fifth lower in class three obesity, with a parallel gradient in disease activity scores that reached about half a point higher in the most obese group. Crucially, no such gradient appeared in the placebo arms, which argues this is genuine effect modification rather than obesity simply making disease activity look worse. Heterogeneity was low and risk of bias was low. Practically, this means a patient with class three obesity who plateaus on a Janus kinase inhibitor may be under-responding for metabolic rather than immunological reasons, and weight management deserves to be framed as part of disease-modifying care rather than a lifestyle aside. That thread continues in RMD Open, where a systematic literature review updating the EULAR points to consider for difficult-to-treat rheumatoid arthritis screened over eight and a half thousand records and included one hundred and thirty-one studies [4]. In patients who had already failed two or more biologic or targeted synthetic agents, essentially all agents except otilimab beat placebo, and meta-regression showed that Janus kinase inhibitor efficacy was maintained even as the number of prior biologic failures rose from one to three or more, though most of that evidence carried high risk of bias. The safety signal was equally clear: increased infection and malignancy with Janus kinase inhibitors. So the message is not to avoid this class in refractory disease, but to pair its persistent efficacy with explicit cardiovascular and malignancy risk stratification. Notably, evidence for non-pharmacological options in patients with poor quality of life but low objective disease activity remained thin, with only limited data pointing to orthopaedic surgery.

Turning to connective tissue disease and the lung, Arthritis and Rheumatology reports real-world outcomes from the ILD-PRO Registry, a prospective multicentre United States cohort of five hundred and eighty-five patients with progressive pulmonary fibrosis associated with systemic autoimmune rheumatic disease [5]. These patients were already advanced at enrolment, with a median forced vital capacity of about sixty-five percent predicted and a median diffusing capacity of thirty-eight percent predicted; nearly forty percent were on supplemental oxygen, three-quarters were on immunomodulatory therapy, and only about a fifth were taking nintedanib. By two years, between roughly a third and just over sixty percent had progressed depending on subtype, and between nine and thirty-eight percent had died or undergone lung transplant. Rheumatoid arthritis-associated disease looked worst unadjusted, but once age, sex and baseline lung function were accounted for, no subtype differences remained. The implication is that the underlying rheumatic diagnosis matters less than the fibrotic phenotype and baseline severity, which argues for phenotype-focused risk stratification, systematic pulmonary monitoring, and earlier antifibrotic consideration rather than waiting for the label to dictate urgency. That fits neatly with a review in Nature Reviews Rheumatology comparing the recent EULAR recommendations, British Society for Rheumatology guidelines, and the interstitial lung disease guidance from the American College of Rheumatology with the American College of Chest Physicians, the 2025 European Respiratory Society-EULAR guidelines, and the American Thoracic Society [1]. The authors find the methodologies robust and the recommendations broadly aligned, with divergence mostly reflecting differences in scope rather than genuine disagreement about best practice, which is reassuring when you are trying to reconcile several documents at the bedside.

Vasculitis and polymyalgia bring us the week's steroid-sparing theme. Also in Nature Reviews Rheumatology, a review of eosinophilic granulomatosis with polyangiitis makes the case that this disease is still managed with strategies borrowed from microscopic polyangiitis and granulomatosis with polyangiitis, despite its distinguishing feature being chronic upper and lower airway involvement that drives prolonged glucocorticoid exposure [6]. Interleukin-5 pathway blockade with mepolizumab or benralizumab controls persistent respiratory symptoms and reduces steroid need, but the role of these agents at diagnosis and over the long term remains undefined, and data on agents targeting interleukin-4, interleukin-13 and thymic stromal lymphopoietin are retrospective with unestablished safety. Alongside this, RMD Open reports a retrospective comparative cohort using United States Medicare fee-for-service claims in steroid-treated polymyalgia rheumatica, matching four hundred and fifteen treatment pairs starting either an interleukin-6 receptor inhibitor or a conventional synthetic immunomodulator [3]. Interleukin-6 receptor blockade was associated with roughly a thirty percent greater likelihood of discontinuing glucocorticoids or reaching minimal use of two milligrams a day or less by one year. The trade-off appeared early: hospitalised infection rates in the first year were roughly double with interleukin-6 receptor inhibition, about twelve versus six per hundred patient-years, though by year two the rates converged. Other adverse events were low and comparable. So counsel patients that the infection risk is front-loaded and warrants close monitoring in those first months.

Finally, osteoarthritis, where two papers pull in opposite directions on how much optimism is warranted. An expert perspective in Arthritis and Rheumatology takes aim at low dose radiation therapy, which is being actively marketed to rheumatology divisions across the United States and has even acquired German guidelines [7]. The author's reading is that the evidence base is sparse, largely observational, and that accumulating data suggest no incremental benefit over placebo, while the placebo effect in osteoarthritis is so powerful that it functions almost as active therapy. Until randomised double-blind trials exist, the advice is to be circumspect before referring patients for radiation. Contrast that with Annals of the Rheumatic Diseases, reporting two-year results of a phase one open-label study of an intra-articular gene therapy delivering interleukin-1 receptor antagonist under an inflammation-inducible promoter in moderate-to-severe knee osteoarthritis [8]. Across seventy-two patients, the main treatment-related event was transient knee effusion, less frequent when intra-articular methylprednisolone was given first, thirty-six versus sixty-one percent, and biodistribution outside the joint was minimal, with detectable vector in plasma in only two participants. Among those still enrolled at two years, and note that nearly half had discontinued, pain, stiffness and function improvements persisted regardless of pre-existing neutralising antibodies. This is exploratory, uncontrolled, and subject to exactly the placebo caveat the radiation piece raises, so it should be read as a safety and feasibility signal, not evidence of efficacy.

If you only have time for one paper this week, make it the Lancet Rheumatology individual patient data meta-analysis on body mass index and Janus kinase inhibitor response [2]. It is a rigorous, placebo-controlled demonstration that obesity blunts response to a class we now use constantly, and it changes what you say to patients at the point of prescribing.

Here are the key takeaways from this week in Rheumatology. First, higher body mass index progressively blunts Janus kinase inhibitor response in rheumatoid arthritis, with no equivalent gradient on placebo, so weight management belongs in the treatment plan. Second, in difficult-to-treat disease, Janus kinase inhibitors retain efficacy after multiple biologic failures but demand explicit infection, malignancy and cardiovascular risk stratification. Third, in autoimmune progressive pulmonary fibrosis, outcomes track baseline severity and phenotype rather than the rheumatic label, and patients are being enrolled already severely impaired, so monitor systematically and act early. Fourth, interleukin-6 receptor inhibition spares steroids more effectively than conventional agents in refractory polymyalgia rheumatica, at the cost of a front-loaded hospitalised infection risk. And fifth, in osteoarthritis, hold the line on low dose radiation therapy until controlled trials exist, while watching intra-articular gene therapy as an early-stage prospect only.

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.